Please ensure Javascript is enabled for purposes of website accessibility

Md. firm’s brain function technology supported in journal findings

BrainScope Co. Inc's. BrainScope One aims to help clinicians provide a rapid, objective assessment of mild head injury, including concussion. (Business Wire photo)

BrainScope Co. Inc’s. BrainScope One aims to help clinicians provide a rapid, objective assessment of mild head injury, including concussion. (Business Wire photo)

A technology used in a Maryland firm’s head injury assessment device had findings about it published in a peer-reviewed journal.

Findings from a multi-site trial of Bethesda-based BrainScope Co. Inc.’s brain function index in the early diagnosis of brain injury were published online in the Journal of Neurotrauma.  The index is a core part of its BrainScope One device for rapid assessment of mildly presenting adult head-injured patients.

BrainScope in September 2016 received FDA clearance to market the device when it was using an older name for it, “Ahead 300.”

The findings support the index as a marker of brain function impairment, which scaled with severity of impairment in mild brain injury patients, according to BrainScope.

The lead author of the study is Dr. Daniel Hanley Jr., a professor and the director of the Brain Injury Outcomes Program at the Johns Hopkins University School of Medicine.

This is the 21st peer-reviewed publication supporting BrainScope’s technology, according to the company.